{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:47:21Z","timestamp":1782424041007,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Marfan syndrome (MFS) is a connective tissue disorder caused by\n                    <jats:italic>FBN1<\/jats:italic>\n                    mutations, characterised by aortic aneurysms leading to life-threatening dissections. Asprosin is the C-terminal propeptide of fibrillin-1 that was shown to function as a glucogenic hormone with critical implications in vascular pathology. However, its role in MFS remains unknown. Here, we investigate the effect of asprosin overexpression in vascular smooth muscle cells (VSMCs) and in the Marfan mouse model\n                    <jats:italic>mgR\/mgR<\/jats:italic>\n                    via endothelial-targeted transduction by adeno-associated viruses (AAVs). In both human and murine VSMCs, asprosin overexpression did not alter VCAM1 or MMP9 expression, while TNF-\u03b1-stimulated asprosin-overexpressing MOVAS cells exhibited reduced IL6 levels. In\n                    <jats:italic>mgR\/mgR<\/jats:italic>\n                    mice, asprosin overexpression did not affect aortic diameter or elastin integrity. Molecular analyses revealed no significant change in inflammatory or epithelial-to-mesenchymal transition (EMT) markers at the mRNA or protein level, with VCAM1 and MMP9 remaining unchanged. Together, these findings indicate that asprosin overexpression does not ameliorate the aneurysmal phenotype in MFS.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-59187-2","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:25:07Z","timestamp":1782415507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aortic asprosin overexpression does not ameliorate disease pathophysiology in a murine model of Marfan syndrome"],"prefix":"10.1038","volume":"16","author":[{"given":"Prithviraj Manohar Vijaya","family":"Shetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Michalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Witthaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Noormalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Marcous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Morcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Bozoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Warnecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kupatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Scherlie\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Sengle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Kliesow Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"59187_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41572-021-00298-7","volume":"7","author":"DM Milewicz","year":"2021","unstructured":"Milewicz, D. M. et al. Marfan syndrome. Nat. Rev. Dis. Primer. 7, 64 (2021).","journal-title":"Nat. Rev. Dis. Primer"},{"key":"59187_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.repc.2019.09.008","volume":"39","author":"SG Coelho","year":"2020","unstructured":"Coelho, S. G. & Almeida, A. G. Marfan syndrome revisited: From genetics to the clinic. Rev. Port Cardiol. 39, 215\u2013226 (2020).","journal-title":"Rev. Port Cardiol."},{"key":"59187_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1172\/JCI200422399","volume":"114","author":"PH Byers","year":"2004","unstructured":"Byers, P. H. Determination of the molecular basis of Marfan syndrome: a growth industry. J. Clin. Investig. 114, 161\u2013163 (2004).","journal-title":"J. Clin. Investig."},{"key":"59187_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/352337a0","volume":"352","author":"HC Dietz","year":"1991","unstructured":"Dietz, H. C. et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352, 337\u2013339 (1991).","journal-title":"Nature"},{"key":"59187_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1006\/geno.1993.1350","volume":"17","author":"GM Corson","year":"1993","unstructured":"Corson, G. M., Chalberg, S. C., Dietz, H. C., Charbonneau, N. L. & Sakai, L. Y. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5\u2019 end. Genomics 17, 476\u2013484 (1993).","journal-title":"Genomics"},{"key":"59187_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0070-2153(06)75004-9","volume":"75","author":"D Hubmacher","year":"2006","unstructured":"Hubmacher, D., Tiedemann, K. & Reinhardt, D. P. Fibrillins: from biogenesis of microfibrils to signaling functions. Curr. Top. Dev. Biol. 75, 93\u2013123 (2006).","journal-title":"Curr. Top. Dev. Biol."},{"key":"59187_CR7","doi-asserted-by":"publisher","first-page":"e002039","DOI":"10.1161\/CIRCGEN.117.002039","volume":"11","author":"L Mui\u00f1o-Mosquera","year":"2018","unstructured":"Mui\u00f1o-Mosquera, L. et al. Tailoring the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines for the interpretation of sequenced variants in the FBN1 gene for Marfan syndrome: Proposal for a disease- and gene-specific guideline. Circ. Genomic Precis Med. 11, e002039 (2018).","journal-title":"Circ. Genomic Precis Med."},{"key":"59187_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere, C. et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell 165, 566\u2013579 (2016).","journal-title":"Cell"},{"key":"59187_CR9","doi-asserted-by":"publisher","first-page":"108614","DOI":"10.1016\/j.jdiacomp.2023.108614","volume":"37","author":"H Diao","year":"2023","unstructured":"Diao, H., Li, X., Xu, Y., Xing, X. & Pang, S. Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus. J. Diabetes Complicat. 37, 108614 (2023).","journal-title":"J. Diabetes Complicat."},{"key":"59187_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mce.2019.03.001","volume":"486","author":"T Lee","year":"2019","unstructured":"Lee, T., Yun, S., Jeong, J. H. & Jung, T. W. Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation. Mol. Cell. Endocrinol. 486, 96\u2013104 (2019).","journal-title":"Mol. Cell. Endocrinol."},{"key":"59187_CR11","doi-asserted-by":"publisher","first-page":"101397","DOI":"10.1016\/j.tice.2020.101397","volume":"66","author":"N Kocaman","year":"2020","unstructured":"Kocaman, N. & Kulo\u011flu, T. Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue Cell. 66, 101397 (2020).","journal-title":"Tissue Cell."},{"key":"59187_CR12","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41598-022-05060-x","volume":"12","author":"YAT Morcos","year":"2022","unstructured":"Morcos, Y. A. T. et al. Sensitive asprosin detection in clinical samples reveals serum\/saliva correlation and indicates cartilage as source for serum asprosin. Sci. Rep. 12, 1340 (2022).","journal-title":"Sci. Rep."},{"key":"59187_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cmet.2019.05.022","volume":"30","author":"E Li","year":"2019","unstructured":"Li, E. et al. OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell. Metab. 30, 319\u2013328e8 (2019).","journal-title":"Cell. Metab."},{"key":"59187_CR14","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/nm.4432","volume":"23","author":"C Duerrschmid","year":"2017","unstructured":"Duerrschmid, C. et al. Asprosin is a centrally acting orexigenic hormone. Nat. Med. 23, 1444\u20131453 (2017).","journal-title":"Nat. Med."},{"key":"59187_CR15","doi-asserted-by":"publisher","first-page":"e33526","DOI":"10.1097\/MD.0000000000033526","volume":"102","author":"L Zhu","year":"2023","unstructured":"Zhu, L. & Wang, L. Serum asprosin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome: A retrospective case-control study. Medicine (Baltim). 102, e33526 (2023).","journal-title":"Medicine (Baltim)."},{"key":"59187_CR16","doi-asserted-by":"crossref","unstructured":"Mishra, I. et al. Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. eLife 10, e63784 (2021).","DOI":"10.7554\/eLife.63784"},{"key":"59187_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10753-022-01761-7","volume":"46","author":"Q Huang","year":"2023","unstructured":"Huang, Q. et al. Asprosin exacerbates endothelium inflammation induced by hyperlipidemia through activating IKK\u03b2-NF-\u03baBp65 pathway. Inflammation 46, 623\u2013638 (2023).","journal-title":"Inflammation"},{"key":"59187_CR18","doi-asserted-by":"publisher","first-page":"2103867","DOI":"10.1002\/advs.202103867","volume":"9","author":"T Bozoglu","year":"2022","unstructured":"Bozoglu, T. et al. Endothelial retargeting of AAV9 in vivo. Adv. Sci. 9, 2103867 (2022).","journal-title":"Adv. Sci."},{"key":"59187_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fendo.2020.00064","volume":"11","author":"M Yuan","year":"2020","unstructured":"Yuan, M., Li, W., Zhu, Y., Yu, B. & Wu, J. Asprosin: A novel player in metabolic diseases. Front. Endocrinol. 11, 64 (2020).","journal-title":"Front. Endocrinol."},{"key":"59187_CR20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jtcvs.2007.12.063","volume":"136","author":"R He","year":"2008","unstructured":"He, R. et al. Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms. J. Thorac. Cardiovasc. Surg. 136, 922\u2013929 (2008). 929.e1.","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"59187_CR21","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1073\/pnas.96.7.3819","volume":"96","author":"L Pereira","year":"1999","unstructured":"Pereira, L. et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc. Natl. Acad. Sci. 96, 3819\u20133823 (1999).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"59187_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.omtm.2021.02.017","volume":"21","author":"A Remes","year":"2021","unstructured":"Remes, A. et al. Alginate hydrogel polymers enable efficient delivery of a vascular-targeted AAV vector into aortic tissue. Mol. Ther. Methods Clin. Dev. 21, 83\u201393 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"59187_CR23","doi-asserted-by":"publisher","first-page":"115280","DOI":"10.1016\/j.bcp.2022.115280","volume":"205","author":"M Zaradzki","year":"2022","unstructured":"Zaradzki, M. et al. Short-term rapamycin treatment increases life span and attenuates aortic aneurysm in a murine model of Marfan-Syndrome. Biochem. Pharmacol. 205, 115280 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"59187_CR24","doi-asserted-by":"publisher","first-page":"101163","DOI":"10.1016\/j.omtm.2023.101163","volume":"32","author":"M Noormalal","year":"2024","unstructured":"Noormalal, M. et al. Regnase-1 overexpression as a therapeutic approach of Marfan syndrome. Mol. Ther. Methods Clin. Dev. 32, 101163 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"59187_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cca.2017.10.034","volume":"489","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Chen, C., Zhou, N., Fu, Y. & Cheng, X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin. Chim. Acta Int. J. Clin. Chem. 489, 183\u2013188 (2019).","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"59187_CR26","doi-asserted-by":"publisher","first-page":"131868","DOI":"10.1016\/j.ijbiomac.2024.131868","volume":"268","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Asprosin aggravates atherosclerosis via regulating the phenotype transformation of vascular smooth muscle cells. Int. J. Biol. Macromol. 268, 131868 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"59187_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12967-022-03542-0","volume":"20","author":"J Zou","year":"2022","unstructured":"Zou, J., Xu, C., Zhao, Z. W., Yin, S. H. & Wang, G. Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38\/Elk-1 pathway. J. Transl Med. 20, 337 (2022).","journal-title":"J. Transl Med."},{"key":"59187_CR28","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1097\/HJH.0000000000003751","volume":"42","author":"ZQ Xu","year":"2024","unstructured":"Xu, Z. Q. et al. Asprosin contributes to vascular remodeling in hypertensive rats via superoxide signaling. J. Hypertens. 42, 1427\u20131439 (2024).","journal-title":"J. Hypertens."},{"key":"59187_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jcp.20549","volume":"207","author":"CW Lee","year":"2006","unstructured":"Lee, C. W. et al. Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation. J. Cell. Physiol. 207, 174\u2013186 (2006).","journal-title":"J. Cell. Physiol."},{"key":"59187_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.HYP.33.1.183","volume":"33","author":"S Goetze","year":"1999","unstructured":"Goetze, S. et al. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 33, 183\u2013189 (1999).","journal-title":"Hypertension"},{"key":"59187_CR31","first-page":"641","volume":"62","author":"H Zelov\u00e1","year":"2013","unstructured":"Zelov\u00e1, H. & Ho\u0161ek, J. TNF-\u03b1 signalling and inflammation: interactions between old acquaintances. Inflamm. Res. Off J. Eur. Histamine Res. Soc. Al. 62, 641\u2013651 (2013).","journal-title":"Inflamm. Res. Off J. Eur. Histamine Res. Soc. Al"},{"key":"59187_CR32","doi-asserted-by":"publisher","first-page":"e31659","DOI":"10.1016\/j.heliyon.2024.e31659","volume":"10","author":"R Ge","year":"2024","unstructured":"Ge, R. et al. Asprosin promotes vascular inflammation via TLR4-NF\u03baB-mediated NLRP3 inflammasome activation in hypertension. Heliyon 10, e31659 (2024).","journal-title":"Heliyon"},{"key":"59187_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/oby.23656","volume":"31","author":"Y Lu","year":"2023","unstructured":"Lu, Y. et al. Asprosin aggravates vascular endothelial dysfunction via disturbing mitochondrial dynamics in obesity models. Obes. Silver Spring Md. 31, 732\u2013743 (2023).","journal-title":"Obes. Silver Spring Md."},{"key":"59187_CR34","doi-asserted-by":"publisher","first-page":"e178198","DOI":"10.1172\/JCI178198","volume":"135","author":"J Huang","year":"2025","unstructured":"Huang, J. et al. Inhibition of aortic CX3CR1\u2009+\u2009macrophages mitigates thoracic aortic aneurysm progression in Marfan syndrome in mice. J. Clin. Invest. 135, e178198 (2025).","journal-title":"J. Clin. Investig."},{"key":"59187_CR35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/biomedicines9091171","volume":"9","author":"J Rysz","year":"2021","unstructured":"Rysz, J., Gluba-Brz\u00f3zka, A., Rokicki, R. & Franczyk, B. Oxidative stress-related susceptibility to Aneurysm in Marfan\u2019s syndrome. Biomedicines 9, 1171 (2021).","journal-title":"Biomedicines"},{"key":"59187_CR36","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jtcvs.2019.05.043","volume":"159","author":"NM Gensicke","year":"2020","unstructured":"Gensicke, N. M. et al. Accelerated Marfan syndrome model recapitulates established signaling pathways. J. Thorac. Cardiovasc. Surg. 159, 1719\u20131726 (2020).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"59187_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.matbio.2017.07.004","volume":"71\u201372","author":"F Ramirez","year":"2018","unstructured":"Ramirez, F., Caescu, C., Wondimu, E. & Galatioto, J. Marfan syndrome; A connective tissue disease at the crossroads of mechanotransduction, TGF\u03b2 signaling and cell stemness. Matrix Biol. J. Int. Soc. Matrix Biol. 71\u201372, 82\u201389 (2018).","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"59187_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1083\/jcb.200608167","volume":"176","author":"SS Chaudhry","year":"2007","unstructured":"Chaudhry, S. S. et al. Fibrillin-1 regulates the bioavailability of TGFbeta1. J. Cell. Biol. 176, 355\u2013367 (2007).","journal-title":"J. Cell. Biol."},{"key":"59187_CR39","doi-asserted-by":"crossref","unstructured":"Alonso, F. et al. Fibrillin-1 regulates endothelial sprouting during angiogenesis. Proc. Natl. Acad. Sci. USA  120, e2221742120 (2023).","DOI":"10.1073\/pnas.2221742120"},{"key":"59187_CR40","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gt.2011.143","volume":"19","author":"K Varadi","year":"2012","unstructured":"Varadi, K. et al. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800\u2013809 (2012).","journal-title":"Gene Ther."},{"key":"59187_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/hgtb.2017.192","volume":"28","author":"A Jungmann","year":"2017","unstructured":"Jungmann, A., Leuchs, B., Rommelaere, J., Katus, H. A. & M\u00fcller, O. J. Protocol for efficient generation and characterization of adeno-associated viral vectors. Hum. Gene Ther. Methods 28, 235\u2013246 (2017).","journal-title":"Hum. Gene Ther. Methods"},{"key":"59187_CR42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/ATVBAHA.114.305150","volume":"35","author":"JR Cook","year":"2015","unstructured":"Cook, J. R. et al. Dimorphic effects of transforming growth factor-\u03b2 signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler. Thromb. Vasc Biol. 35, 911\u2013917 (2015).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"59187_CR43","doi-asserted-by":"publisher","first-page":"e0164778","DOI":"10.1371\/journal.pone.0164778","volume":"11","author":"L Lee","year":"2016","unstructured":"Lee, L. et al. Aortic and Cardiac Structure and Function Using High-Resolution Echocardiography and Optical Coherence Tomography in a Mouse Model of Marfan Syndrome. PLoS One 11, e0164778 (2016).","journal-title":"PLoS One"},{"key":"59187_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omtn.2017.08.014","volume":"9","author":"R Arif","year":"2017","unstructured":"Arif, R. et al. AP-1 Oligodeoxynucleotides Reduce Aortic Elastolysis in a Murine Model of Marfan Syndrome. Mol. Ther. Nucleic Acids. 9, 69\u201379 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"59187_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.110.012187","volume":"124","author":"D McLoughlin","year":"2011","unstructured":"McLoughlin, D. et al. Pravastatin reduces Marfan aortic dilation. Circulation 124, 168\u2013173 (2011).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59187-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59187-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59187-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:02:14Z","timestamp":1782421334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59187-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59187"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59187-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19608"}}